On Monday, Allogene Therapeutics Inc (NASDAQ: ALLO) was 9.76% up from the session before settling in for the closing price of $1.23. A 52-week range for ALLO has been $0.86 – $3.78.
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.26%. When this article was written, the company’s average yearly earnings per share was at 29.47%. With a float of $159.44 million, this company’s outstanding shares have now reached $223.16 million.
Allogene Therapeutics Inc (ALLO) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Allogene Therapeutics Inc stocks. The insider ownership of Allogene Therapeutics Inc is 29.05%, while institutional ownership is 50.57%. The most recent insider transaction that took place on Nov 17 ’25, was worth 959. In this transaction SVP, Chief Technical Officer of this company sold 786 shares at a rate of $1.22, taking the stock ownership to the 217,721 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 786 for $1.22, making the entire transaction worth $959.
Allogene Therapeutics Inc (ALLO) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.28 earnings per share (EPS) during the time that was better than consensus figure (set at -0.32) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.61% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
You can see what Allogene Therapeutics Inc (ALLO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.88 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Looking closely at Allogene Therapeutics Inc (NASDAQ: ALLO), its last 5-days average volume was 2.62 million, which is a drop from its year-to-date volume of 3.95 million. As of the previous 9 days, the stock’s Stochastic %D was 61.67%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 51.83%, which indicates a significant decrease from 100.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0871 in the past 14 days, which was lower than the 0.0873 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2388, while its 200-day Moving Average is $1.3640. However, in the short run, Allogene Therapeutics Inc’s stock first resistance to watch stands at $1.3933. Second resistance stands at $1.4367. The third major resistance level sits at $1.5233. If the price goes on to break the first support level at $1.2633, it is likely to go to the next support level at $1.1767. Now, if the price goes above the second support level, the third support stands at $1.1333.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
There are 224,730K outstanding shares of the company, which has a market capitalization of 303.39 million. As of now, sales total 20 K while income totals -257,590 K. Its latest quarter income was 0 K while its last quarter net income were -41,400 K.
